TY - JOUR
T1 - 177Lu-Prostate-Specific Membrane Antigen Ligand after 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer
T2 - Real-World Clinical Experience
AU - Sartor, Oliver
AU - la Fougère, Christian
AU - Essler, Markus
AU - Ezziddin, Samer
AU - Kramer, Gero
AU - Ellinger, Jörg
AU - Nordquist, Luke
AU - Sylvester, John
AU - Paganelli, Giovanni
AU - Peer, Avivit
AU - Bögemann, Martin
AU - Meltzer, Jeffrey
AU - Sandström, Per
AU - Verholen, Frank
AU - Song, Daniel Y.
N1 - Funding Information:
Oliver Sartor reports grants or fees from Amgen, Bayer, Sanofi, AstraZeneca, Dendreon, Constellation Pharmaceuticals, Advanced Accelerator Applications, Endocyte, Pfizer, Bristol Myers Squibb, Bavarian Nordic, EMD Serono, Astellas Pharma, Progenics, Blue Earth Diagnostics, Merck, Invitae, Astellas, Endocyte, Myovant Sciences, Myriad Genetics, Novartis, Clarity Pharmaceuticals, Fusion Pharmaceuticals, Isotopen Technologien, Janssen, Noxo-pharm, Clovis Oncology, Taiho, Noria Therapeutics, Point Bio-pharma, TeneoBio, Telix Pharmaceuticals, and Theragnostics. Christian la Fougère serves as a consultant/adviser for Bayer and Sanofi-Aventis. Markus Essler reports research funding from Novartis; is a consultant/adviser for Bayer, Novartis, and Ipsen; and receives travel expenses from Ipsen and Sirtex. Samer Ezzid-din reports travel expenses from Ipsen. Jorg Ellinger serves as a consultant for Bayer. John Sylvester reports employment at 21st Century Oncology; research funding from Prostatak (via 21st Century Oncology); stock in Augmenix; patents, royalties, or other intellectual properties with Myriad; and honoraria from Decipher and Theragenics. John Sylvester also serves as a consultant/adviser for, receives travel expenses from, and is on the speakers’ bureau for Theragenics. Avivit Peer serves as a consultant/adviser for Pfizer, BMS, Roche, Eisai, MSD, Janssen, Astel-las, Novartis, Medison, AstraZeneca, and Bayer. Jeffrey Meltzer, Per Sandstrom, and Frank Verholen are employees of Bayer. Daniel Song reports research funding from Bayer, Advantagene, Bristol Myers Squibb, and BioProtect and serves as a consultant/ adviser for BioProtect. This work was supported by Bayer Healthcare Pharmaceuticals Inc., Whippany, NJ, USA. No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
COPYRIGHT © 2022 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - We analyzed real-world clinical outcomes of sequential a-/b-emitter therapy for metastatic castration-resistant prostate cancer (mCRPC). Methods: We assessed safety and overall survival in 26 patients who received 177Lu-prostate-specific membrane antigen ligand (177Lu-PSMA) after 223Ra in the ongoing noninterventional REASSURE study (223Ra a-Emitter Agent in Nonintervention Safety Study in mCRPC Population for Long-Term Evaluation; NCT02141438). Results: Patients received 223Ra for a median of 6 injections and subsequent 177Lu-PSMA for a median of 3.5 mo ($ the fourth therapy in 69%). The median time between 223Ra and 177Lu-PSMA treatment was 8 mo (range, 1-31 mo). Grade 3 hematologic events occurred in 9 of 26 patients (during or after 177Lu-PSMA treatment in 5/9 patients; 8/9 patients had also received docetaxel). Median overall survival was 28.0 mo from the 223Ra start and 13.2 mo from the 177Lu-PSMA start. Conclusion: Although the small sample size precludes definitive conclusions, these preliminary data, especially the 177Lu-PSMA treatment duration, suggest that the use of 177Lu-PSMA after 223Ra is feasible in this real-world setting.
AB - We analyzed real-world clinical outcomes of sequential a-/b-emitter therapy for metastatic castration-resistant prostate cancer (mCRPC). Methods: We assessed safety and overall survival in 26 patients who received 177Lu-prostate-specific membrane antigen ligand (177Lu-PSMA) after 223Ra in the ongoing noninterventional REASSURE study (223Ra a-Emitter Agent in Nonintervention Safety Study in mCRPC Population for Long-Term Evaluation; NCT02141438). Results: Patients received 223Ra for a median of 6 injections and subsequent 177Lu-PSMA for a median of 3.5 mo ($ the fourth therapy in 69%). The median time between 223Ra and 177Lu-PSMA treatment was 8 mo (range, 1-31 mo). Grade 3 hematologic events occurred in 9 of 26 patients (during or after 177Lu-PSMA treatment in 5/9 patients; 8/9 patients had also received docetaxel). Median overall survival was 28.0 mo from the 223Ra start and 13.2 mo from the 177Lu-PSMA start. Conclusion: Although the small sample size precludes definitive conclusions, these preliminary data, especially the 177Lu-PSMA treatment duration, suggest that the use of 177Lu-PSMA after 223Ra is feasible in this real-world setting.
UR - http://www.scopus.com/inward/record.url?scp=85125552917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125552917&partnerID=8YFLogxK
U2 - 10.2967/JNUMED.121.262240
DO - 10.2967/JNUMED.121.262240
M3 - Article
C2 - 34168015
AN - SCOPUS:85125552917
SN - 0161-5505
VL - 63
SP - 410
EP - 414
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 3
ER -